Physician profile
Jonathan Love
NPI 1790212041
$2,523.57
in general payments reported to CMS, 2019-2025
16 companies · $583 in 2025
The $583 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $412 · 2023: $664 · 2024: $865 · 2025: $583.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,099 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,099.36 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $581.49 | 2022-2025 | Caplyta |
| Abbvie INC. | $382.54 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $244.43 | 2022-2025 | Rexulti, Abilify Mycite, Abilify Asimtufii |
| Bausch Health US, LLC | $187.41 | 2022-2023 | Aplenzin, Wellbutrin |
| Takeda Pharmaceuticals U.S.A., INC. | $177.63 | 2023-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $161.33 | 2022-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $139.91 | 2023-2025 | Ingrezza |
| Lundbeck LLC | $131.32 | 2022-2023 | Rexulti |
| Alkermes, INC. | $116.24 | 2023-2025 | Aristada, Lybalvi |
| Supernus Pharmaceuticals, INC. | $83.56 | 2023-2024 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $78.50 | 2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $73.72 | 2022-2024 | Spravato |
| Sage Therapeutics, LLC | $58.49 | 2024-2025 | Zurzuvae |
| Tempus Ai, INC | $56.36 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $35.78 | 2025 | Uzedy |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $14.86 | 2024 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Love listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.